Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption stops the synthesis of DNA, RNA and proteins, thereby reducing the proliferation of rapidly dividing cells such as activated immune cells and cancerous lymphocytes.

The dose of Metoject is individualized. A qualified prescriber determines the amount, frequency and route based on the specific indication, patient weight, renal function and other clinical factors. No standard dosing can be quoted without a medical prescription.

Metoject is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations or death. It is also not recommended while breastfeeding, as methotrexate can be excreted in milk and affect the infant.

To request Metoject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with biologic agents used for rheumatoid arthritis or psoriasis, methotrexate is a small‑molecule drug that can be administered by injection and is generally less expensive. However, biologics may have a more targeted mechanism and a different safety profile, while methotrexate offers broad immunosuppressive activity useful in both autoimmune and oncologic settings.

Metoject should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or particulate.

Metoject is supplied as an injectable solution and can be given intramuscularly, intravenously or subcutaneously, depending on the clinical indication and prescriber preference. Administration is performed by a qualified healthcare professional using aseptic technique.

The most critical adverse events include severe liver toxicity, pulmonary fibrosis, and bone‑marrow suppression leading to pancytopenia. Patients should be monitored regularly for liver enzyme elevations, respiratory symptoms and blood‑count abnormalities, and treatment should be stopped if any of these serious reactions occur.

Metoject is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic or renal impairment, and those with active, uncontrolled infections. Caution is also advised for patients with pre‑existing lung disease or immunodeficiency.